WHC is still in active development. Read this to understand our approach.
depiction of AKOOIMKXADOPDA-UHFFFAOYSA-N.svg
tripsit

ab-fubinaca

Verificar en tripsit

psychonaut

AB-FUBINACA

Verificar en psychonaut

isomerdesign

AB-FUBINACA

Verificar en isomerdesign

druglab

AB-FUBINACA

Verificar en druglab

wiki

AB-FUBINACA

Verificar en wiki

Data

InChI: InChI=1S/C20H21FN4O2/c1-12(2)17(19(22)26)23-20(27)18-15-5-3-4-6-16(15)25(24-18)11-13-7-9-14(21)10-8-13/h3-10,12,17H,11H2,1-2H3,(H2,22,26)(H,23,27)

Sinónimos: FT-0696685,Nalpha-[1-(4-Fluorobenzyl)-1H-indazole-3-ylcarbonyl]-L-valinamide,BDBM50249590,Q4650002,ab-fub,ZINC95705073,I7PZF0KTFK,1H-INDAZOLE-3-CARBOXAMIDE, N-((1S)-1-(AMINOCARBONYL)-2-METHYLPROPYL)-1-((4-FLUOROPHENYL)METHYL)-,CHEMBL4083220,N-[(1S)-1-(aminocarbonyl)-2-methylpropyl]-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide,DTXSID70728845,N-((1S)-1-(aminocarbonyl)-2-methylpropyl]-1-((4-fluorophenyl)methyl)-1H-indazole-3-carboxamide,DEA No. 7012,N-[(2S)-1-Amino-3-methyl-1-oxobutan-2-yl]-1-[(4-fluorophenyl)methyl]-1H-indazole-3-carboxamide,1185282-01-2,UNII-I7PZF0KTFK,AMB-FUBINACA,AB-FUBINACA,SCHEMBL1217062,AKOS022174913,NCGC00390276-01,N-[(1S)-1-carbamoyl-2-methyl-propyl]-1-[(4-fluorophenyl)methyl]indazole-3-carboxamide,(S)-N-(1-Amino-3-methyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide,N-[(1S)-1-(Aminocarbonyl)-2-methylpropyl]-1-[(4-fluorophenyl)methyl]-1H-indazole-3-carboxamide,N-[(1S)-1-(aminocarbonyl)-2-methylpropyl]-1-[(4-fluorophenyl)methyl]-1H-indazole-3-carboxamide,N-((1S)-1-(AMINOCARBONYL)-2-METHYLPROPYL)-1-((4-FLUOROPHENYL)METHYL)-1H-INDAZOLE-3-CARBOXAMIDE,N-[(2S)-1-amino-3-methyl-1-oxobutan-2-yl]-1-[(4-fluorophenyl)methyl]indazole-3-carboxamide

Estimated data

Solubilidad: -3.962 (log(S) in mol/L prediction using SolTranNet)

Blood Brain Barrier Permeability: No (prediction using frontiersin.org)

Addictivity Prediction: 86.5% (prediction based on www.mdpi.com)

Similitudes

The following is a set of comparisons to understand the properties of this compound. This is still higly experimental and is still under active development. Please refer to our series of blog posts to fully understand our approach and its limitations. This information is for informational purposes only and should not be construed as medical advice.